newsfilter
← Latest News
Business Wire·

Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update

- NDA Submission for Seralutinib in PAH On Track for September 2026 Following Receipt of Pre-NDA Type B Meeting Minutes - - Gossamer Reacquired Worldwide Development and Commercial Rights to Seralutinib from Chiesi,